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93.7% in age group 1 (0 ≤ 12 years) to 83.3% in age group 5 (older than 65 years). 
In general the lowest average reﬁ ll-based adherence rates were obtained with medicine 
items containing phenobarbitone and vitamin B1 (52.0% ± 37.8); phenobarbitone 
(63.5% ± 47.2); primidone metabolites (69.7% ± 47.2%); clonazepam (77.8% ± 
184.8) and carbamazepine (80.9% ± 151.1) CONCLUSIONS: Most of the anti-epi-
leptic drugs had unacceptable low reﬁ ll-adherence rates. Reﬁ ll-adherence rates of 
anti-epileptic drugs decreased with an increase in the age of patients.
PND33
REFILL-ADHERENCE RATES OF ANTIPARKINSON MEDICATION IN THE 
PRIVATE HEALTH CARE SECTOR OF SOUTH AFRICA
Van der Merwe S, Lubbe MS, Du Plessis JM, Bekker E
North-West University, Potchefstroom, South Africa
OBJECTIVES: To investigate the prevalence of unacceptable reﬁ ll-based adherence 
rates with antiparkinson medicine items. METHODS: A retrospective drug utilization 
study was performed on medicine claims data of a pharmacy beneﬁ t management 
company in South Africa during January 1, 2005 until December 31, 2008. Reﬁ ll-
based adherence rates were calculated for 8 768 antiparkinson medicine items that 
were prescribed more than once during a four-year period (January 1, 2005 to Decem-
ber 2008). The reﬁ ll-based adherence rate was calculated per trade name by using the 
following equation: Reﬁ ll-Adherence rate = (total number of days of antiparkinson 
medicine items supplied—days supplied at the last reﬁ ll)/(date last claimed—date ﬁ rst 
claimed). (RSA Rand(R)/$US = 6.8595 on 31 Dec. 2007). [RSA Rand (R)/$US = 
6.38112 (2005); 6.78812 (2006); 7.06926 (2007) and 8.27505 (2008)] RESULTS: A 
majority of antiparkinson medicine items (53.50%, n = 4,691) had unacceptably low 
reﬁ ll-adherence rates below 90%, that accounted for 41.62% (n = R16,398,512.00) 
of the total cost (N = R39,402,898.20) of all antiparkinson medicine items included 
in this study. Only 36.78% (n = 3225) of antiparkinson medicine items had acceptable 
reﬁ ll-adherence rates between 90% and 110%. Those with unacceptable high reﬁ ll-
adherence rates accounted for 9.72% (n = 852) of all antiparkinson medicine items 
and represented 6.5% (n = R2,574,597) of the total cost. No practical signiﬁ cant 
difference in the average reﬁ ll-adherence rates was found between male (93.99% ± 
186.99) and female (90.83% ± 175.21) patients. Biperidien, carbidopa/levodopa, and 
levodopa/benserazide containing products had on average unacceptable low reﬁ ll-
adherence rates (<90%). CONCLUSIONS: Although poor obedience to treatment 
schedules adds up to aggravation of Parkinson’s disease leading to death and ampliﬁ ed 
health care cost, it seems that the reﬁ ll-adherence rate of antiparkinson medicine items 
is not very favourable
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OBJECTIVES: The Scales for Outcomes in Patients with Parkinson’s disease Diary 
Card (SCOPA-DC) is a daily diary designed to measure motor impairment in Parkin-
son’s disease (PD) patients with ﬂ uctuating symptoms. Previous qualitative research 
evaluated the content validity of the SCOPA-DC in the US and expanded it to measure 
non-motor symptoms. The current research examined the psychometric properties of 
the revised SCOPA-DC. METHODS: A sample of adults age 30 and older with self-
reported doctor-conﬁ rmed PD were recruited, screened, and consented online from a 
Knowledge Networks panel. Eligible patients were mailed a study packet that con-
tained the revised SCOPA-DC as well as a training video. The revised SCOPA-DC 
included 7 non-motor items: fatigue, memory, anxiety, pain, difﬁ culty swallowing, 
frequent urination, and sweating. The diary was completed 7 times per day for 3 
consecutive days. Consistent with the original SCOPA-DC, 3-day scores were calcu-
lated for each item. Higher scores indicated greater symptom severity. RESULTS: A 
total of 101 PD patients completed and returned the revised SCOPA-DC. The sample 
was 50.5% male and had been diagnosed with PD for an average of 7.4 years. Fre-
quency distributions showed little missing data (approximately 1.0%), although items 
were generally right-skewed. Fatigue (29.4) and walking (28.7) had the highest mean 
scores; sweating (7.3) and difﬁ culty swallowing (9.7) had the lowest mean scores. 
Factor analysis supported a 3-factor solution: mobility, physical functioning, and 
psychological functioning. These factors demonstrated good internal consistency 
(alpha = 0.83–0.87) and correlations with health-related quality of life instruments 
were suggestive of construct validity. CONCLUSIONS: In this US sample of PD 
patients with varied disease severity, the revised SCOPA-DC exhibited good psycho-
metric properties, including evidence of reliability and validity. Furthermore, patients 
reported that the revised SCOPA-DC was clear and easy to complete. The revised 
SCOPA-DC holds promise for measuring a broad spectrum of ﬂ uctuating motor and 
non-motor PD symptoms.
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OBJECTIVES: There has been increasing interest novel HTA methods that will incor-
porate patient preferences in a more transparent and scientiﬁ cally valid way. The 
fundamental problem of the assessment of beneﬁ ts in HTA is the identiﬁ cation, 
ranking and valuation of multiple health care outcomes. We used two multi-criteria 
methods to rank and value ﬁ ve different treatments in stroke rehabilitation. Analytic 
Hierarchy Process (AHP) stems from operations research and is increasingly being 
used in health care to weigh patient-reported endpoints. Conjoint analysis (CA) is a 
stated preference method that often takes the discrete choice format. In CA, hypotheti-
cal scenarios are used to generate part-worth utilities for attributes. METHODS: To 
determine the clinical decision context and related criteria, a paper-and-pencil ques-
tionnaire was conducted among a sample of Dutch physiatrists united in a stroke 
interest group. From the lists of criteria (e.g. clinical beneﬁ t, impact of treatment) an 
expert panel deﬁ ned the AHP decision structure as well as the conjoint analysis survey 
format. Finally, the complete questionnaire including the AHP and CA survey was 
sent out to 184 patients with ankle-foot impairments. Eventually, 89 patients com-
pleted both surveys. RESULTS: On average, the prediction of preferred treatment on 
a group level is similar for both AHP and CA. However. on an inidividual level there 
seems to be more variation in treatment preference. Using AHP weights, a vast major-
ity preferred soft-tissue surgery where most patients preferred orthopedic shoes if CA 
weights were used. This may have been caused by labelling effects of the attributes. 
CONCLUSIONS: Both methods have there pros and cons in ranking and valuing 
patient-reported endpoints. Of the methods AHP is relatively easy to apply. In predic-
tion of overall outcome, both methods perform equally. However, for individual 
treatment preference we observed some differences. It may be concluded that the 
decision structure, framing and labelling of the treatment attributes are more impor-
tant than the speciﬁ c elicitation method used.
PND36
HEALTH STATUS COMPARISON BETWEEN STABLE PARKINSON’S 
DISEASE PATIENTS AND THOSE EXPERIENCING OFF-TIME
Buck PO1, White RE1, Castelli-Haley J1, Rendas-Baum R2, White MK2
1Teva Neuroscience, Kansas City, MO, USA; 2QualityMetric Incorporated, Lincoln, RI, USA
OBJECTIVES: End-of-dose wearing-off is commonly experienced by Parkinson’s 
disease (PD) patients who have used dopaminergic therapy for several years. Although 
investigations of wearing-off have traditionally focused on motor ﬂ uctuations, it is 
increasingly recognized that non-motor symptoms also vary between periods of “ON” 
(when PD symptoms are minimized due to medication) and “OFF” (when PD symp-
toms return). This study characterizes the self-reported health status of PD patients 
who experienced OFF-time as compared to those who were stable. METHODS: 
Recruited from an online panel maintained by Knowledge Networks, adults with 
self-reported doctor-conﬁ rmed PD were screened, consented, and completed a cross-
sectional survey. Frequency of OFF-time was measured using the Uniﬁ ed Parkinson’s 
Disease Rating Scale Part IV. Demographics, PD-speciﬁ c characteristics, the 9-item 
Wearing-off Questionnaire (WOQ-9), the Short Form-12v2 (SF-12), and the Parkin-
son’s Disease Questionnaire-8 (PDQ-8) were also assessed. RESULTS: Data were 
available for 165 PD patients (mean age = 66.6 years; 52.7% male; mean time from 
diagnosis = 7.1 years). Twenty-ﬁ ve (15%) of the patients reported experiencing no 
OFF-time on a typical day and were classiﬁ ed as stable; the remaining 85% reported 
experiencing OFF-time. There were few signiﬁ cant differences between the two groups 
in terms of demographics and PD history. Compared to those experiencing OFF-time, 
stable patients reported fewer motor and non-motor wearing-off symptoms based on 
the WOQ-9 (P < 0.05), as well as better health on the Physical and Mental Component 
Summary scores of the SF-12 (P < 0.05) and the Summary Index score of the PDQ-8 
(P < 0.01). CONCLUSIONS: PD patients who experienced at least some OFF-time 
on a typical day reported worse overall physical and mental well-being than stable 
patients. Furthermore, both motor and non-motor wearing-off symptoms differed 
between the two patient groups. Additional research to understand the consequences 
of OFF-time would be useful, especially as it pertains to non-motor symptoms.
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OBJECTIVES: To compare patients’ and physicians’ global perceptions of Parkinson’s 
disease (PD) in two treatment groups: levodopa/carbidopa/entacapone (LCE) vs. 
levodopa/carbidopa (LC). METHODS: Multicentre, double-blind, randomised phase 
IV study. Ninety-ﬁ ve PD patients with early wearing-off (WO) and deterioration of 
activities of daily living (ADLs) were randomised to receive LCE (n = 46) or LC (n = 
49) with a 3-month follow-up. Patient and physician global perception of PD was 
assessed at the end of the study. The PDQ-39 quality of life (QoL) questionnaire, and 
the longitudinal course of PD using the different parts of UPDRS (part I, part II, part 
III, and IV) were evaluated along the study. Differences between health improvement 
by patient and physician were analyzed by the Mann Whitney U-test. The mean dif-
ferences from baseline to ﬁ nal visit in PDQ-39 and in UPDRS (part I, II, IIII IV) score 
were analyzed by an ANCOVA model. RESULTS: Mean (SD) age was 66.4 ± 8.6 
years and 50.0% were women. Half percent of patients showed stage II according to 
the Hoehn and Yahr classiﬁ cation. Patient global perception showed a signiﬁ cant 
better score in the LCE than in LC group (−0.9 ± 1.0 LCE and −0.4 ± 1.17 LC, p = 
0. 0291). Similar results were obtained by the physician (−0.3 ± 0.8 vs. −0.4, p = 0. 
0017). The adjusted mean differences in the PDQ-39 showed a trend for a higher 
improvement in QoL in the LCE group (6.3 ± 20.4 vs. 0.81 ± 15.6), although did not 
reach statistical signiﬁ cance. The UPDRS evaluation showed a signiﬁ cant higher 
